These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 23238854)

  • 21. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
    Shumaker SA; Legault C; Rapp SR; Thal L; Wallace RB; Ockene JK; Hendrix SL; Jones BN; Assaf AR; Jackson RD; Kotchen JM; Wassertheil-Smoller S; Wactawski-Wende J;
    JAMA; 2003 May; 289(20):2651-62. PubMed ID: 12771112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Progestogens, progesterone, coagulation and vascular tone].
    Schved JF; Biron C
    Gynecol Obstet Fertil; 2002 May; 30(5):421-6. PubMed ID: 12087938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progestogen safety and tolerance in hormonal replacement therapy.
    Palacios S; Mejía A
    Expert Opin Drug Saf; 2016 Nov; 15(11):1515-1525. PubMed ID: 27548404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The choice of progestogen for HRT in menopausal women: breast cancer risk is a major issue.
    Ruan X; Mueck AO
    Horm Mol Biol Clin Investig; 2018 Aug; 37(1):. PubMed ID: 30120909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progesterone receptor isoform ratios influence the transcriptional activity of progestins via the progesterone receptor.
    Cartwright M; Louw-du Toit R; Jackson H; Janse van Vuuren M; Africander D
    J Steroid Biochem Mol Biol; 2023 Sep; 232():106348. PubMed ID: 37315868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
    Heald A; Kaushal K; Anderson S; Redpath M; Durrington PN; Selby PL; Gibson MJ
    Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy.
    Gompel A
    Climacteric; 2018 Aug; 21(4):321-325. PubMed ID: 29583028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships between chemical structure and biological properties of progestogens.
    Rozenbaum H
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):719-24. PubMed ID: 7065053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.
    Chlebowski RT; Hendrix SL; Langer RD; Stefanick ML; Gass M; Lane D; Rodabough RJ; Gilligan MA; Cyr MG; Thomson CA; Khandekar J; Petrovitch H; McTiernan A;
    JAMA; 2003 Jun; 289(24):3243-53. PubMed ID: 12824205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
    Simoncini T; Genazzani AR
    Climacteric; 2010 Feb; 13(1):22-33. PubMed ID: 19938948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast cancer risk during hormone therapy: experimental versus clinical data.
    Ruan X; Seeger H; Mueck AO
    Minerva Endocrinol; 2012 Mar; 37(1):59-74. PubMed ID: 22382615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
    Cauley JA; Robbins J; Chen Z; Cummings SR; Jackson RD; LaCroix AZ; LeBoff M; Lewis CE; McGowan J; Neuner J; Pettinger M; Stefanick ML; Wactawski-Wende J; Watts NB;
    JAMA; 2003 Oct; 290(13):1729-38. PubMed ID: 14519707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Defense of Progesterone: A Review of the Literature.
    Lieberman A; Curtis L
    Altern Ther Health Med; 2017 Nov; 23(6):24-32. PubMed ID: 29055286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of progesterones on blood lipids in hormone replacement therapy.
    Jiang Y; Tian W
    Lipids Health Dis; 2017 Nov; 16(1):219. PubMed ID: 29157280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical evaluation of progestogens used in Menopausal Hormone Therapy (MHT)].
    Mueck AO
    Ther Umsch; 2021; 78(8):447-455. PubMed ID: 34555976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The menopause: benefits and risks of estrogen-progestogen replacement therapy.
    Gambrell RD
    Fertil Steril; 1982 Apr; 37(4):457-74. PubMed ID: 7040116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of progestogens on the postmenopausal breast.
    de Lignières B
    Climacteric; 2002 Sep; 5(3):229-35. PubMed ID: 12419080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy.
    Kwok S; Selby PL; McElduff P; Laing I; Mackness B; Mackness MI; Prais H; Morgan J; Yates AP; Durrington PN; Sci FM
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):760-7. PubMed ID: 15579192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women.
    Kwok S; Charlton-Menys V; Pemberton P; McElduff P; Durrington PN
    Maturitas; 2006 Mar; 53(4):439-46. PubMed ID: 16139447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.